The AIDA Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT-29 human colorectal adenocarcinoma cell line. This loss-of-function model features targeted disruption of the AIDA gene across a heterogeneous cell pool, enabling study of AIDA??s regulatory roles without the confounding effects of clonal selection. The polyclonal nature preserves biological variability and is suitable for population-level assays commonly employed in signal transduction research. These cells are ideal for investigating the consequences of AIDA ablation on Wnt/??-catenin signaling and associated cellular phenotypes.
HT-29 cells are adherent epithelial cells derived from a colorectal adenocarcinoma of a 44-year-old female, extensively used as a model for intestinal epithelial biology and colorectal cancer. They exhibit characteristic features of colon carcinoma, including constitutively active Wnt/??-catenin signaling, and retain the capacity to differentiate along an intestinal lineage. This well-characterized background provides a physiologically relevant platform for dissecting the tumor-suppressive functions of AIDA in colon carcinogenesis. The HT-29 line??s genetic makeup and signaling proficiency make it particularly suited for exploring the interplay between AIDA and key oncogenic pathways.
AIDA encodes a scaffold protein that negatively regulates the Wnt/??-catenin pathway through direct interaction with Axin (AXIN1, AXIN2) and Dishevelled (DVL1, DVL2). By disrupting the Axin-Dvl complex, AIDA prevents ??-catenin stabilization and nuclear accumulation, repressing TCF/LEF-mediated transcription of target genes such as MYC and CCND1. AIDA functions downstream of WNT ligands like WNT3A and intersects with the JNK cascade, further linking it to planar cell polarity. Its interactions with CTNNB1 (??-catenin) and APC underscore its pivotal role in modulating the Wnt signalosome.
In HT-29 cells, loss of AIDA removes a critical brake on Wnt/??-catenin signaling, intensifying the already elevated transcriptional activity that drives proliferation, migration, and survival. This polyclonal knockout model thus enables precise evaluation of AIDA??s contribution to tumor-suppressive networks in colorectal cancer. It is particularly valuable for dissecting signal crosstalk, as AIDA loss may sensitize cells to additional pathway modulators, and for assessing the dependency of colon cancer cells on AIDA-mediated regulation of ??-catenin/TCF activity.
These polyclonal knockout cells are well-suited for a diverse array of research applications, including Wnt pathway dissection, colorectal cancer biology, and drug screening for Wnt inhibitors. Researchers can perform assays such as TOP/FOP Flash reporter assays, RT-qPCR for MYC and CCND1, Western blotting for AIDA and ??-catenin, co-immunoprecipitation of Axin-Dvl complexes, immunofluorescence for ??-catenin subcellular localization, and phenotypic studies of proliferation, migration, and apoptosis. For additional technical information or to discuss custom applications, please contact Ascent Research.
